The use of three comparator groups—general population, patients with RA on anti-TNF-α therapy, and patients with RA on methotrexate and/or placebo—provided a more significant assessment of the risk of lymphoma among recipients of anti-TNF-α. Here, TNF is linked to lymphoma.